Written Question · S2W-07172 · Session 2
In light of the US Food and Drug Administration requesting the label of 10 anti-depressant drugs to include a statement that recommends clo…
The question
To ask the Scottish Executive, in light of the US Food and Drug Administration requesting the label of 10 anti-depressant drugs to include a statement that recommends close observation of the patients for worsening depression or the warning signs of suicide and the fact that nine of these drugs are prescribed in Scotland, what steps will be taken to instruct NHS Quality Improvement Scotland to introduce a monitoring structure in respect of the use and effect of these drugs.
The answer
The regulation and safety ofmedicines is reserved and is the responsibility of the Medicines and Healthcareproducts Regulatory Agency (MHRA).
The safetyof the selective serotonin reuptake inhibitors (SSRIs) has been closely monitoredby the MHRA and the UK independentexpert advisory committee, the Committee on Safety of Medicines (CSM).
The CSMhas considered the question of suicidal behaviour in association with the SSRIson a number of occasions and carefully assessed any new data. The CSM has advisedthat it is general clinical experience that patients taking any anti-depressantmay develop an increase in suicidal behaviour in the first few weeks of treatment.SSRI product information has been amended to include warnings that suicidal behaviourmay increase in the early stages of treatment with any anti-depressant and thatpatients should be carefully monitored during this period. The CSM advice is availableon www.mhra.gov.uk.
The CSM'sExpert Working Group on the safety of SSRIs is currently reviewing the availableevidence relating to the safety of these medicines, with particular reference tobehavioural disorders, including suicidality, to ensure that the advice in the productinformation is optimal for safe use of these products.
The safetyof the selective serotonin reuptake inhibitors (SSRIs) has been closely monitoredby the MHRA and the UK independentexpert advisory committee, the Committee on Safety of Medicines (CSM).
The CSMhas considered the question of suicidal behaviour in association with the SSRIson a number of occasions and carefully assessed any new data. The CSM has advisedthat it is general clinical experience that patients taking any anti-depressantmay develop an increase in suicidal behaviour in the first few weeks of treatment.SSRI product information has been amended to include warnings that suicidal behaviourmay increase in the early stages of treatment with any anti-depressant and thatpatients should be carefully monitored during this period. The CSM advice is availableon www.mhra.gov.uk.
The CSM'sExpert Working Group on the safety of SSRIs is currently reviewing the availableevidence relating to the safety of these medicines, with particular reference tobehavioural disorders, including suicidality, to ensure that the advice in the productinformation is optimal for safe use of these products.
In the Official Report
No contribution in the Official Report cites S2W-07172 by reference.